Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group, Dose-range-finding Study of Two Delayed Release Formulations of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation

Trial Profile

A Phase 2b, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group, Dose-range-finding Study of Two Delayed Release Formulations of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Linaclotide (Primary) ; Linaclotide (Primary)
  • Indications Irritable bowel syndrome
  • Focus Therapeutic Use
  • Sponsors Allergan; Ironwood Pharmaceuticals
  • Most Recent Events

    • 01 May 2023 Results (n=2350) of post hoc analysis pooled from studies (NCT02559206, NCT03573908, NCT00948818, and NCT00938717) published in the American Journal of Gastroenterology
    • 26 Oct 2022 Results(n=2073) of post hoc analysis pooled from studies(NCT02559206,NCT00948818, NCT00938717 and NCT03573908) assessing the Safety and Efficacy of Linaclotide in Patients With Irritable Bowel Syndrome and Constipation presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022
    • 01 Feb 2021 Results published in the American Journal of Gastroenterology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top